PPAR, RXR, and VDR Expressions in Peri-implantitis

ABSTRACT Objective: Periodontitis and peri-implantitis are the irreversible destructive diseases of the periodontal and peri-implant tissues. The present study aimed to determine the receptor expressions of Peroxisome proliferative-activated receptor (PPAR)-γ, Retinoid X receptor (RXR)-α, and Vitamin D receptor (VDR) in the diseased tissues around teeth and dental implants.

Methods: The study consisted of three groups as group 1; healthy controls (C, n=15), group 2; periodontitis patients with stage 3 grade B (P, n=15), and group 3; peri-implantitis patients (PI, n=15). Periodontal clinical parameters as the plaque index (PI), gingival index (GI) and clinical attachment levels (CAL) were recorded. Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing. Hematoxylin-eosin (H&E) and immunohistochemistry staining were performed. Total inflammatory cell counts and fibroblast cell density were evaluated on H&E-stained slides while PPAR-γ, RXR-α, and VDR were evaluated via immunohistochemistry.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Periodontitis Mouth Diseases Peri-Implantitis Periimplantitis Periodontal Diseases Stomatognathic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Gaziosmanpasa University

Tokat Province, 60100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

healthy individuals
periodontitis patients
periimplantitis patients

Exclusion criteria

smokers,
systemically compromised patients

Treatment and study plan

Gingival biopsies

Other

Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.

Primary outcomes

Inflammatory cells counts

Time frame: 6 months

Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing. Hematoxylin-eosin (H&E) staining were performed. Total inflammatory cell counts density were evaluated on H&E-stained slides.A cell counting frame of 10.000 µm2 area was selected under 1000x magnification. The total inflammatory cells (neutrophil, lymphocyte, eosinophil, and macrophage cells) within the frame were counted as inflammatory cell counting.
Fibroblast counts

Time frame: 6 months

Fibroblasts counts were evaluated from H&E stained slides under 1000x magnification via a light microscope (Nikon Eclipse, E 600, Tokyo, Japan).
Peroxisome proliferative-activated receptor (PPAR)-γ

Time frame: During histological processing

Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processin and immunohistochemistry staining were performed, PPAR-γ, was evaluated via immunohistochemistry. Samples were examined under 400x magnification using light microscopy (Nikon Eclipse, E 600, Tokyo, Japan).
Retinoid X receptor (RXR)-α

Time frame: 6 months

Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing and immunohistochemistry staining were performed, RXR-α was evaluated via immunohistochemistry. Samples were examined under 400x magnification using light microscopy (Nikon Eclipse, E 600, Tokyo, Japan).
Vitamin D receptor (VDR)

Time frame: 6 months

. Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing and immunohistochemistry staining were performed, VDR was evaluated via immunohistochemistry. Samples were examined under 400x magnification using light microscopy (Nikon Eclipse, E 600, Tokyo, Japan).

Sponsors and collaborators

Lead sponsor

Tokat Gaziosmanpasa University

Other

Registry information

Official study title

PPAR-γ, RXR, and VDR Expressions in Gingival Tissue Samples of Healthy Individuals, Periodontitis and Peri-implantitis Patients

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: Jul 15, 2019
Registry last updated: Jul 15, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting